Hepatitis vs Liver Cancer — Clinical Trial Comparison
Hepatitis
Viral liver inflammation (B and C most common)
VS
Liver Cancer
Primary liver cancer (hepatocellular carcinoma)
Hepatitis and liver cancer are intimately connected — chronic hepatitis B and C are the leading causes of hepatocellular carcinoma (HCC) worldwide. In the UK, hepatitis C can now be cured in over 95% of cases with direct-acting antivirals, while hepatitis B remains a chronic management challenge. Liver cancer trials have been transformed by immunotherapy combinations.
Key Differences at a Glance
| Feature | Hepatitis | Liver Cancer |
|---|---|---|
| UK prevalence | ~200,000 living with chronic HBV or HCV | ~6,100 new liver cancer cases/year |
| Key biomarkers | HBV DNA, HCV RNA, ALT, HBsAg, HBeAg, fibrosis stage | AFP, DCP, tumour size/number, Child-Pugh class, BCLC stage |
| Screening available | Targeted (at-risk groups, NHS HBV screening in pregnancy) | Surveillance for cirrhosis patients (ultrasound + AFP every 6 months) |
| Curability | HCV: curable (>95% with DAAs). HBV: suppressible | Early stage: potentially curable. Advanced: palliative |
| NICE first-line | DAAs (HCV), entecavir/tenofovir (HBV) | Atezolizumab + bevacizumab (advanced HCC), surgery/transplant (early) |
| Link between conditions | Chronic HBV/HCV leads to cirrhosis and HCC | ~50-60% of HCC cases linked to chronic hepatitis |
Clinical Trial Availability
| Trial Aspect | Hepatitis | Liver Cancer |
|---|---|---|
| UK trials actively recruiting | 20-40 studies | 30-50 studies |
| Most common trial phase | Phase 2-3 | Phase 2-3 |
| Top interventions tested | DAAs (HCV), capsid inhibitors, siRNA (HBV), therapeutic vaccines | Immunotherapy combos, TKIs, ADCs, locoregional + systemic |
| Curative intent trials | Major focus for HCV (functional cure for HBV) | Early stage only (transplant, resection, ablation) |
| Prevention trials | Active (HBV vaccination, HCV elimination) | Active (surveillance optimisation, chemoprevention) |
| Combination therapy trials | siRNA + capsid inhibitors (HBV), DAA combos (HCV) | Immunotherapy + TKI, dual checkpoint, IO + locoregional |
Exciting Emerging Treatments
Hepatitis Trials
- siRNA therapies (bepirovirsen, JNJ-3989) — silencing HBV DNA for functional cure
- Capsid assembly modulators — disrupting HBV replication
- Therapeutic vaccines — boosting immune response against HBV
- HCV elimination trials — community-based testing and treatment strategies
- Entry inhibitors — blocking HBV from entering new hepatocytes
- Combination functional cure trials — multi-target approach to clear HBsAg
Liver Cancer Trials
- Dual immunotherapy — durvalumab + tremelimumab (HIMALAYA regimen)
- Next-generation TKIs — lenvatinib combinations, novel multi-kinase inhibitors
- Antibody-drug conjugates — targeting GPC3 and other HCC antigens
- Locoregional + immunotherapy — TACE or Y90 combined with checkpoint inhibitors
- Biomarker-driven trials — selecting patients by immune profile and genetics
- Emerging cell therapy — CAR-T and bispecifics for HCC
💡 Not sure which trials you qualify for?
Use our Smart Matcher to answer a few questions about your condition and we'll find the most relevant trials for your specific situation — free, instant results.
Eligibility Differences
Hepatitis Trial Criteria
- Confirmed HBV (HBsAg positive 6+ months) or HCV (HCV RNA positive) diagnosis
- HBV DNA or HCV RNA viral load thresholds commonly required
- Fibrosis stage assessment needed (FibroScan, biopsy, or serum markers)
- Prior treatment history documented (DAA-experienced for HCV, nucleos(t)ide-exposed for HBV)
- Coinfection status (HIV/HBV, HBV/HCV, HDV) affects trial eligibility
Liver Cancer Trial Criteria
- Confirmed HCC diagnosis (imaging criteria or biopsy)
- Child-Pugh liver function class (A or early B for most systemic therapy trials)
- BCLC stage determines treatment approach (early, intermediate, advanced)
- Portal vein invasion status critical (excludes some treatment options)
- Underlying liver disease aetiology documented (HBV, HCV, NASH, alcohol)
Frequently Asked Questions
Can I join a clinical trial if I have both Hepatitis and Liver Cancer?
It depends on the specific trial. Many trials allow comorbid conditions as long as the primary condition being studied is clearly dominant. Some trials explicitly exclude patients with significant overlapping conditions. Always check the eligibility criteria carefully and discuss with both the trial team and your specialist.
Which condition has more clinical trials available in the UK?
Both Hepatitis and Liver Cancer have robust research pipelines with new studies opening regularly. The number of trials varies over time as new studies launch and others complete. Check our condition pages for the most current trial availability.
What should I consider when choosing between trials for these conditions?
Consider which condition impacts your quality of life most, what treatments you've already tried, the trial phase (earlier phases are more experimental), the time commitment involved, and whether the trial offers access to treatments not otherwise available. Your specialist can help you prioritise.